This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmaco…

ALK Positive Non-small Cell Lung Cancer

~Estimated

~$10 – $8,750

Chugai PharmaceuticalNCT07617337

Phase 1

A Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer …

ALK PositiveALK Positive Non-small Cell Lung CancerNSCLC+1 more

~Estimated

~$10 – $8,750

Nuvectis Pharma, Inc.NCT07784959